Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus CLOCORTOLONE PIVALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus CLOCORTOLONE PIVALATE.
ARAZLO vs CLOCORTOLONE PIVALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Clocortolone pivalate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Topical: Apply a thin film to affected area once or twice daily. Not for ophthalmic use. Maximum duration of 2 weeks per course.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is approximately 2.5 hours (range 1-4 hours), reflecting rapid clearance; clinical duration exceeds half-life due to tissue binding.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal (approximately 80%) as glucuronide and sulfate conjugates; minor biliary/fecal excretion (20%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid